on MEDINCELL (EPA:MEDCL)
Medincell: 2024 revenues on the rise and significant clinical progress
Medincell has announced an upward revision to its 2024 revenue guidance for UZEDY®. Initially estimated at $80 million, revenue is now expected to be between $80 million and $100 million. In 2024, sales in the United States have already reached $75 million.
In parallel, the phase 3 clinical trial of Olanzapine LAI reached a major milestone. No cases of post-injection delirium/sedation syndrome (PDSS) were observed after 100% of the planned injections. This absence of PDSS could make Olanzapine LAI safer and more accessible.
Medincell is expected to receive royalties and $105 million in milestones related to UZEDY®. The company, in partnership with Teva Pharmaceuticals, continues to advance the development of innovative medical solutions.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDINCELL news